Corvus Pharmaceuticals Announces Board Changes and New Director

Corvus Pharmaceuticals ( (CRVS) ) just unveiled an update.

On April 22, 2026, Corvus Pharmaceuticals’ board appointed Andrew C. Chan, M.D., Ph.D., as a Class II director and member of the Nominating and Corporate Governance Committee, effective April 23, 2026, with a term running through the 2027 annual shareholder meeting. His compensation package includes a prorated annual cash retainer, an initial stock option grant for 30,000 shares under the company’s 2016 equity plan, additional fees for committee service, and eligibility for future equity awards, along with entry into the company’s standard director indemnification agreement.

Also on April 22, 2026, long-serving director Scott Morrison notified Corvus of his intention to resign from the board effective April 23, 2026, after more than a decade of service, including as chair of the audit committee. The board transition replaces a seasoned financial and audit leader with a new director and governance committee member, marking a notable change in board composition and oversight as the company moves into its next phase of development.

The most recent analyst rating on (CRVS) stock is a Buy with a $40.00 price target. To see the full list of analyst forecasts on Corvus Pharmaceuticals stock, see the CRVS Stock Forecast page.

Spark’s Take on CRVS Stock

According to Spark, TipRanks’ AI Analyst, CRVS is a Neutral.

The score is held back primarily by weak financial performance typical of a pre-revenue biotech (no revenue, sizable and worsening cash burn/operating losses). This is partially offset by a favorable earnings-call backdrop highlighting promising early clinical efficacy/safety signals and an extended cash runway after the $189M financing. Technicals are mixed with near-term weakness but a still-positive longer-term trend; valuation offers limited support due to the negative P/E and no dividend yield data.

To see Spark’s full report on CRVS stock, click here.

More about Corvus Pharmaceuticals

Corvus Pharmaceuticals, Inc. is a biopharmaceutical company focused on developing innovative pharmaceutical products. The company operates in the life sciences industry, where it relies on an experienced board and governance structure to guide its strategy, capital allocation, and oversight of clinical and corporate initiatives.

Average Trading Volume: 1,518,118

Technical Sentiment Signal: Buy

Current Market Cap: $1.44B

Find detailed analytics on CRVS stock on TipRanks’ Stock Analysis page.